Fremanezumab Decreases Migraine Symptoms such as Nausea, Vomiting, Photophobia and Phonophobia and Reduces the Need for Acute Medications in the First Week of Treatment in the HFEM Study (P4.111)

Fremanezumab was effective and well-tolerated as a preventive treatment for migraine in a 3 month phase 2 high frequency episodic migraine (HFEM) study. The present post-hoc analyses evaluated the efficacy of two doses of subcutaneous fremanezumab (225 mg and 675 mg) during the first three weeks of therapy in patients with high frequency episodic migraine (HFEM) to relieve symptoms associated with migraine pain such as nausea, vomiting, photophobia and phonophobia and their use of acute medications.